Masimo (NASDAQ:MASI) Shares Gap Up After Analyst Upgrade

Masimo Co. (NASDAQ:MASIGet Free Report)’s stock price gapped up prior to trading on Monday after Stifel Nicolaus raised their price target on the stock from $125.00 to $148.00. The stock had previously closed at $134.93, but opened at $153.76. Stifel Nicolaus currently has a hold rating on the stock. Masimo shares last traded at $148.04, with a volume of 428,801 shares trading hands.

Other equities research analysts have also issued research reports about the stock. BTIG Research raised their price target on shares of Masimo from $145.00 to $166.00 and gave the stock a “buy” rating in a research note on Monday. Piper Sandler raised their price target on shares of Masimo from $70.00 to $117.00 and gave the stock a “neutral” rating in a research note on Monday, February 26th. Jefferies Financial Group restated a “hold” rating and set a $121.00 price target (up previously from $107.00) on shares of Masimo in a research note on Tuesday, January 30th. StockNews.com downgraded shares of Masimo from a “hold” rating to a “sell” rating in a report on Thursday, March 21st. Finally, Needham & Company LLC downgraded shares of Masimo from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, Masimo presently has an average rating of “Hold” and an average target price of $134.29.

Read Our Latest Report on MASI

Institutional Trading of Masimo

Several institutional investors and hedge funds have recently made changes to their positions in MASI. Massmutual Trust Co. FSB ADV raised its position in Masimo by 140.6% in the 4th quarter. Massmutual Trust Co. FSB ADV now owns 243 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 142 shares during the period. Byrne Asset Management LLC purchased a new position in shares of Masimo in the fourth quarter valued at about $28,000. DHJJ Financial Advisors Ltd. purchased a new position in shares of Masimo in the third quarter valued at about $32,000. NBC Securities Inc. purchased a new position in shares of Masimo in the third quarter valued at about $34,000. Finally, EverSource Wealth Advisors LLC increased its position in shares of Masimo by 851.6% in the fourth quarter. EverSource Wealth Advisors LLC now owns 295 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 264 shares during the period. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Masimo Price Performance

The business’s 50-day simple moving average is $130.91 and its 200-day simple moving average is $108.77. The stock has a market cap of $7.38 billion, a PE ratio of 92.34 and a beta of 0.95. The company has a quick ratio of 1.22, a current ratio of 2.18 and a debt-to-equity ratio of 0.64.

Masimo (NASDAQ:MASIGet Free Report) last announced its earnings results on Tuesday, February 27th. The medical equipment provider reported $1.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.82 by $0.43. The firm had revenue of $548.90 million for the quarter, compared to analyst estimates of $545.69 million. Masimo had a net margin of 3.98% and a return on equity of 13.77%. The company’s revenue for the quarter was down 11.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.32 EPS. On average, research analysts expect that Masimo Co. will post 3.51 EPS for the current fiscal year.

Masimo Company Profile

(Get Free Report)

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

Recommended Stories

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.